NO157368B - Fremgangsmaate til fremstilling av faste legemiddeltilberedninger inneholdende nifedipin. - Google Patents
Fremgangsmaate til fremstilling av faste legemiddeltilberedninger inneholdende nifedipin. Download PDFInfo
- Publication number
- NO157368B NO157368B NO812879A NO812879A NO157368B NO 157368 B NO157368 B NO 157368B NO 812879 A NO812879 A NO 812879A NO 812879 A NO812879 A NO 812879A NO 157368 B NO157368 B NO 157368B
- Authority
- NO
- Norway
- Prior art keywords
- nifedipine
- preparation
- specific surface
- crystals
- preparations containing
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 27
- 238000000034 method Methods 0.000 title claims description 11
- 239000007787 solid Substances 0.000 title claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 30
- 229960001597 nifedipine Drugs 0.000 claims description 30
- 239000013078 crystal Substances 0.000 claims description 11
- 239000013543 active substance Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000969 carrier Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 230000036211 photosensitivity Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000004438 BET method Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19803033919 DE3033919A1 (de) | 1980-09-09 | 1980-09-09 | Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung |
Publications (2)
Publication Number | Publication Date |
---|---|
NO812879L NO812879L (no) | 1982-03-10 |
NO157368B true NO157368B (no) | 1987-11-30 |
Family
ID=6111496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO812879A NO157368B (no) | 1980-09-09 | 1981-08-25 | Fremgangsmaate til fremstilling av faste legemiddeltilberedninger inneholdende nifedipin. |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0047899B2 (ja) |
JP (1) | JPS5914446B2 (ja) |
AR (1) | AR226377A1 (ja) |
AT (1) | ATE5761T1 (ja) |
AU (1) | AU558331B2 (ja) |
CA (1) | CA1180277A (ja) |
DD (1) | DD201974A5 (ja) |
DE (2) | DE3033919A1 (ja) |
DK (1) | DK154326C (ja) |
FI (1) | FI72648B (ja) |
GR (1) | GR78237B (ja) |
HU (1) | HU184879B (ja) |
IE (1) | IE51549B1 (ja) |
IL (1) | IL63749A (ja) |
NO (1) | NO157368B (ja) |
NZ (1) | NZ198285A (ja) |
PH (1) | PH24097A (ja) |
PL (1) | PL232951A1 (ja) |
PT (1) | PT73603B (ja) |
ZA (1) | ZA816213B (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264446A (en) * | 1980-09-09 | 1993-11-23 | Bayer Aktiengesellschaft | Solid medicament formulations containing nifedipine, and processes for their preparation |
JPS5846019A (ja) * | 1981-09-14 | 1983-03-17 | Kanebo Ltd | 持続性ニフエジピン製剤 |
DE3222367A1 (de) * | 1982-06-15 | 1983-12-15 | Bayer Ag, 5090 Leverkusen | Verwendung von 1,4-dihydropyridinen in antiarteriosklerotika und deren herstellung |
JPS59101423A (ja) * | 1982-12-02 | 1984-06-12 | Takada Seiyaku Kk | 新規なニフエジピン固形製剤 |
US4529733A (en) * | 1983-04-06 | 1985-07-16 | Merrell Dow Pharmaceuticals Inc. | Antihypertensive 3-furoyl-1,4-dihydropyridines |
DE3318649A1 (de) * | 1983-05-21 | 1984-11-22 | Bayer Ag, 5090 Leverkusen | Zweiphasenformulierung |
NL194389C (nl) * | 1984-06-14 | 2002-03-04 | Novartis Ag | Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager. |
IT1178511B (it) * | 1984-09-14 | 1987-09-09 | Pharmatec Spa | Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio |
IT1187751B (it) * | 1985-10-15 | 1987-12-23 | Eurand Spa | Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute |
US4940556A (en) * | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
US5198226A (en) * | 1986-01-30 | 1993-03-30 | Syntex (U.S.A.) Inc. | Long acting nicardipine hydrochloride formulation |
CH673947A5 (ja) * | 1986-09-23 | 1990-04-30 | Sandoz Ag | |
JPS6464659A (en) * | 1987-09-03 | 1989-03-10 | Kenbi Kogaku Kenkyusho Kk | Preparation of safe and effective powder formulation |
SE8703881D0 (sv) * | 1987-10-08 | 1987-10-08 | Haessle Ab | New pharmaceutical preparation |
DE3814532A1 (de) * | 1988-04-29 | 1989-11-09 | Bayer Ag | Dhp-retard-zubereitung |
JPH0298550U (ja) * | 1989-01-25 | 1990-08-06 | ||
GB8903328D0 (en) * | 1989-02-14 | 1989-04-05 | Ethical Pharma Ltd | Nifedipine-containing pharmaceutical compositions and process for the preparation thereof |
US5271944A (en) * | 1991-04-05 | 1993-12-21 | Biofor, Ltd. | Pharmacologically enhanced formulations |
DE4130173A1 (de) * | 1991-09-11 | 1993-03-18 | Bayer Ag | Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters |
GB9200607D0 (en) * | 1992-01-13 | 1992-03-11 | Ethical Pharma Ltd | Pharmaceutical compositions containing nifedipine and process for the preparation thereof |
US6726930B1 (en) | 1993-09-09 | 2004-04-27 | Penwest Pharmaceuticals Co. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US5543099A (en) * | 1994-09-29 | 1996-08-06 | Hallmark Pharmaceutical, Inc. | Process to manufacture micronized nifedipine granules for sustained release medicaments |
WO1996020707A1 (de) * | 1994-12-29 | 1996-07-11 | Dr. Rentschler Arzneimittel Gmbh & Co. | Pharmazeutische zubereitungen, enthaltend nifedipin und verfahren zu ihrer herstellung |
JP3220373B2 (ja) | 1995-11-28 | 2001-10-22 | バイエル薬品株式会社 | 持続性ニフエジピン製剤 |
IL123505A (en) * | 1996-07-08 | 2004-12-15 | Penwest Pharmaceuticals Compan | Sustained release matrix for high-dose insoluble drugs |
IT1284604B1 (it) * | 1996-09-27 | 1998-05-21 | Roberto Valducci | Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva |
US6056977A (en) | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
MXPA01005370A (es) | 1999-09-30 | 2004-05-14 | Penwest Pharmaceuticals Co | Sistema de matriz de liberacion sostenida para farmacos altamente solubles. |
EP1741712B1 (en) | 2004-07-30 | 2011-06-15 | Torrent Pharmaceuticals Ltd | amorphous form of nebivolol hydrochloride and its preparation |
DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3330727A (en) * | 1960-04-19 | 1967-07-11 | Glaxo Lab Ltd | Griseofulvin with high specific surface area |
US3401221A (en) * | 1964-08-25 | 1968-09-10 | Norwich Pharma Co | Treatment of urinary tract infection |
DE2348334C2 (de) * | 1973-09-26 | 1982-11-11 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs |
DE2400819C2 (de) * | 1974-01-09 | 1982-04-22 | Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung |
GB1579818A (en) * | 1977-06-07 | 1980-11-26 | Yamanouchi Pharma Co Ltd | Nifedipine-containing solid preparation composition |
JPS55129221A (en) * | 1979-03-29 | 1980-10-06 | Kaken Pharmaceut Co Ltd | Preparation of oral preparation containing hardly soluble medicine |
CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
-
1980
- 1980-09-09 DE DE19803033919 patent/DE3033919A1/de not_active Ceased
- 1980-12-27 JP JP55185148A patent/JPS5914446B2/ja not_active Expired
-
1981
- 1981-08-25 NO NO812879A patent/NO157368B/no unknown
- 1981-08-28 DE DE8181106729T patent/DE3161838D1/de not_active Expired
- 1981-08-28 EP EP81106729A patent/EP0047899B2/de not_active Expired - Lifetime
- 1981-08-28 AT AT81106729T patent/ATE5761T1/de not_active IP Right Cessation
- 1981-08-31 PT PT73603A patent/PT73603B/pt unknown
- 1981-08-31 PH PH26121A patent/PH24097A/en unknown
- 1981-09-01 DD DD81232939A patent/DD201974A5/de not_active IP Right Cessation
- 1981-09-07 GR GR65968A patent/GR78237B/el unknown
- 1981-09-07 FI FI812758A patent/FI72648B/fi not_active Application Discontinuation
- 1981-09-07 NZ NZ198285A patent/NZ198285A/en unknown
- 1981-09-07 IL IL63749A patent/IL63749A/xx not_active IP Right Cessation
- 1981-09-08 CA CA000385365A patent/CA1180277A/en not_active Expired
- 1981-09-08 AR AR286686A patent/AR226377A1/es active
- 1981-09-08 IE IE2075/81A patent/IE51549B1/en not_active IP Right Cessation
- 1981-09-08 ZA ZA816213A patent/ZA816213B/xx unknown
- 1981-09-08 DK DK396381A patent/DK154326C/da not_active IP Right Cessation
- 1981-09-08 AU AU75063/81A patent/AU558331B2/en not_active Expired
- 1981-09-08 PL PL23295181A patent/PL232951A1/xx unknown
- 1981-09-09 HU HU812594A patent/HU184879B/hu unknown
Also Published As
Publication number | Publication date |
---|---|
HU184879B (en) | 1984-10-29 |
PL232951A1 (ja) | 1982-10-11 |
ZA816213B (en) | 1982-09-29 |
EP0047899B1 (de) | 1984-01-04 |
JPS5914446B2 (ja) | 1984-04-04 |
NZ198285A (en) | 1984-04-27 |
EP0047899B2 (de) | 1996-02-28 |
PT73603A (en) | 1981-09-01 |
DK396381A (da) | 1982-03-10 |
NO812879L (no) | 1982-03-10 |
GR78237B (ja) | 1984-09-26 |
DK154326B (da) | 1988-11-07 |
FI72648B (fi) | 1987-03-31 |
ATE5761T1 (de) | 1984-01-15 |
IL63749A0 (en) | 1981-12-31 |
AU558331B2 (en) | 1987-01-29 |
DE3161838D1 (en) | 1984-02-09 |
PH24097A (en) | 1990-03-05 |
IL63749A (en) | 1984-06-29 |
AR226377A1 (es) | 1982-06-30 |
CA1180277A (en) | 1985-01-02 |
PT73603B (en) | 1982-11-10 |
EP0047899A1 (de) | 1982-03-24 |
AU7506381A (en) | 1982-03-18 |
DK154326C (da) | 1995-03-13 |
FI812758L (fi) | 1982-03-10 |
DD201974A5 (de) | 1983-08-24 |
DE3033919A1 (de) | 1982-04-22 |
IE812075L (en) | 1982-03-09 |
JPS5750913A (en) | 1982-03-25 |
IE51549B1 (en) | 1987-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO157368B (no) | Fremgangsmaate til fremstilling av faste legemiddeltilberedninger inneholdende nifedipin. | |
US5264446A (en) | Solid medicament formulations containing nifedipine, and processes for their preparation | |
NO164817B (no) | Fremgangsmaate til fremstilling av tofasede, nifedipinholdige, legemiddeltilberedninger. | |
US5980942A (en) | Zero-order sustained release matrix tablet formulations of carbamazepine | |
AU2002222567B2 (en) | Composition improved in solubility or oral absorbability | |
KR101512404B1 (ko) | 디하이드로피리딘 칼슘 채널 길항제를 포함하는 향상된 의약 조성물 및 이의 준비 방법 | |
US20070196472A1 (en) | Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions | |
NO840770L (no) | Vaesketilbredninger av dihydropyridiner, en fremgangsmaate til deres fremstilling, samt deres anvendelse til bekjempelse av sykdommer | |
US4929605A (en) | Pharmaceutical composition for piperidinoalkanol derivatives | |
HU192407B (en) | Process for producing antidiabetic pharmaceutical compositions for oral application | |
MXPA03005883A (es) | Composiciones farmaceuticas que comprenden maleato de amlodipina. | |
GB2196852A (en) | Sustained release composition | |
US20080274196A1 (en) | Oral Pharmaceutical Suspension Compositions Of Fexofenadine | |
US6020384A (en) | Process for the manufacture of flavanolignan preparation with improved release and absorbability, compositions obtainable thereby and their use for the preparation of pharmaceuticals | |
KR100846945B1 (ko) | 파라세타몰을 포함하는 연하 정제 | |
KR100281521B1 (ko) | 프라바스타틴나트륨이 함유된 약제 조성물 | |
Jachowicz | Dissolution rates of partially water-soluble drugs from solid dispersion systems. II. Phenytoin | |
CN115518066A (zh) | 一种用于治疗抗凝血的药物组合物及应用 | |
EP0310999B1 (en) | Pharmaceutical composition for piperidinoalkanol derivatives | |
CA2728997C (en) | Pharmaceutical composition of levamlodipine or pharmaceutically acceptable salt thereof and .beta. receptor blocking agent, and use thereof | |
RU2141821C1 (ru) | Водная суспензия сабелюзола для орального применения и способ ее изготовления | |
JPS5925765B2 (ja) | 消化性潰瘍治療剤 | |
NO742027L (ja) | ||
JP3061445B2 (ja) | 血管拡張剤 | |
JPS6293230A (ja) | 組合せ製剤 |